Category: Bariatric surgery

24% Reduction in Kidney Events on Semaglutide; TikTok bans Weight Meds Marketing; Bariatric Surgery Cures Infertility; 50% Discontinue GLP-1s at 1y.

24% Reduction in Kidney Events on Semaglutide; TikTok bans Weight Meds Marketing; Bariatric Surgery Cures Infertility; 50% Discontinue GLP-1s at 1y.

AT A GLANCE The American Heart Association ‘…highlights the barriers to treatment and improvements needed in translating the science of obesity to patient care.’ Daniel Gilbert at The Washington Post reports on the ban of TikTok star Taylor Huber who is paid to promote weight-loss medications. The New England Journal of Medicine reports a 24% reduction in kidney disease events, or death from kidney-related or cardiovascular

Read More »
‘South Park’ on Obesity; Novo Trial on Alcoholic Liver Disease; Bernie Sanders Blasts Wegovy Prices; Bariatric Surgery Protects Against Breast Cancer.

‘South Park’ on Obesity; Novo Trial on Alcoholic Liver Disease; Bernie Sanders Blasts Wegovy Prices; Bariatric Surgery Protects Against Breast Cancer.

AT A GLANCE ‘It’s time for some drastic measures to bring down his weight…’ says the doctor in the trailer for South Park: The End of Obesity. STAT on Novo Nordisk to test GLP-1 drugs for people with alcohol-associated liver disease. The Hill on Senate Health Committee Chair Bernie Sanders stating Wegovy could bankrupt US health system. JAMA on bariatric surgery protection against development of breast cancer. STAT on

Read More »
Eli-and-Novo-beat-Q1-Earnings;-Amgen’s-Monthly-Injectable-GLP-1-Candidate;-Ozempic-Babies;-Bariatric-Surgery-Impacts-Kidney-Transplant-Rates

Eli and Novo beat Q1 Earnings; Amgen’s Monthly Injectable GLP-1 Candidate; Ozempic Babies; Bariatric Surgery Impacts Kidney Transplant Rates.

AT A GLANCE Amgen to focus on MariTide, an monthly injectable monoclonal antibody, rather than AMG 786, its early-stage obesity pill, from STAT News. Elaine Chen at STAT notes Eli Lilly raised its full-year guidance on Tuesday while it reported strong first-quarter sales of Zepbound. The Wall Street Journal reports sales of Wegovy more than doubled in the first quarter. Online pharmacies and slimming clinics are cutting prices

Read More »
Costco’s Weight Loss Program; China Develops GLP-1 Drug; Not Everyone Loses Weight on Ozempic; Weed for Weight Loss; GLP-1 For Parkinson’s

Costco’s Weight Loss Program; China Develops GLP-1 Drug; Not Everyone Loses Weight on Ozempic; Weed for Weight Loss; GLP-1 For Parkinson’s

AT A GLANCE USA Today reports ‘…Costco and its low-cost health care partner are expanding into weight-loss management…’ Reuters notes a biosimilar version of Novo Nordisk‚Äôs popular diabetes drug Ozempic has been developed in China Sumathi Reddy at The Wall Street Journal writes some people don’t lose much weight on drugs like Ozempic. Dr. Amir Ghaferi and colleagues from Wisconsin review Metabolic Surgery for Diabetes Management

Read More »
Wegovy for Medicare Beneficiaries; Bariatric Surgery Restrictions Eased by GLP-1 Costs; $6B Spend on GLP-1s by Medicare in 2022; $5 Per Month to Manufacture Ozempic; Viking Therapeutics Stock Charges

Wegovy for Medicare Beneficiaries; Bariatric Surgery Restrictions Eased by GLP-1 Costs; $6B Spend on GLP-1s by Medicare in 2022; $5 Per Month to Manufacture Ozempic; Viking Therapeutics Stock Charges

AT A GLANCE San Diego biotech Viking Therapeutics shares were up 20% on news that the oral version of dual GLP-1/GIP drug VK2735 had succeeded its phase 1 trial. Peter Loftus at The Wall Street Journal reports CVS Health, Elevance Health and Kaiser Permanente would cover Wegovy for Medicare beneficiaries. Miriam E. Tucker at Medscape suggests ‘GLP-1 Costs May Ease Restrictions to Bariatric Surgery.’ The Kaiser Family Foundation analyzed Medicare

Read More »
A Billion People Obese Worldwide; An Obesity Vaccine? – from Novo Nordisk and Vivani; Survodutide for Liver Disease; Bariatric Surgery Cures Diabetes

A Billion People Obese Worldwide; An Obesity Vaccine? – from Novo Nordisk and Vivani; Survodutide for Liver Disease; Bariatric Surgery Cures Diabetes

AT A GLANCE STAT reports on Marcus Schindler, Novo’s chief scientific officer, who wants to ‘…make long-lasting GLP-1 molecules…’ with ‘…vaccine-like properties.’ NPM-115 and NPM-139 are miniature, subdermal GLP-1 implants from NASDAQ-listed company Vivani Medical, Inc. that provide once- or twice-yearly administration. STAT reports from a study in The Lancet that ‘…more than 1 billion people – or one in eight people worldwide –

Read More »
Obamacare and GLP-1 meds; China’s Obesity Crisis; India’s GLP-1 Drugmakers; Bariatric Surgery cures Diabetes; Corporate Ozempic

Obamacare and GLP-1 meds; China’s Obesity Crisis; India’s GLP-1 Drugmakers; Bariatric Surgery cures Diabetes; Corporate Ozempic

AT A GLANCE STAT reports ‘…Obamacare insurance is considering a technical change that would require insurers to cover obesity drugs in a market of more than 20 million Americans.’ Goldman Sachs analysts are featured by Reuters that weight-loss drugs ‘…could boost gross domestic product by 1%.’ Marketing guru Scott Galloway writes ‘…Nobody I know is on Ozempic. Yet, nearly everyone I know is on Ozempic.’ The Wall Street Journal notes China

Read More »
Novo’s-$35B-Spending-Spree;-Mounjaro-Launches-in-Britain;-the-Obesity-Drug-Arms-Race;-Hip-Surgery-and-Semaglutide;-Kids-on-Wegovy

Novo’s $35B Spending Spree; Mounjaro Launches in Britain; the Obesity Drug-Arms Race; Hip Surgery and Semaglutide; Kids on Wegovy

AT A GLANCE Reuters reports Novo Holdings, the controlling shareholder of Danish obesity drugmaker Novo Nordisk, plans to invest about $35 billion by 2030. Eli Lilly launches Mounjaro in Britain this week, for eligible private and NHS patients, from Reuters. Sy Mukherjee at Fast Company notes it is ‘…just the beginning for biopharma’s obesity-drug arms race.’ Patients on semaglutide undergoing hip replacement had lower readmission and

Read More »
Bariatric Surgery Numbers increase in 2022; Wegovy for Depression; Doctors have Fatphobia; Disparities in Obesity Meds; Increased GLP-1 Availability from Novo Nordisk

Bariatric Surgery Numbers increase in 2022; Wegovy for Depression; Doctors have Fatphobia; Disparities in Obesity Meds; Increased GLP-1 Availability from Novo Nordisk

AT A GLANCE Elaine Chen at STAT asks ‘Can Wegovy treat depression as well as obesity?’ The New York Times reports 750,000 state employees in North Carolina will no longer have insurance coverage for GLP-1 medications, as of April 1 2024. Novo Nordisk ‘…had started to increase the availability of its blockbuster obesity drug Wegovy for new patients in the United States…’ from Andrew Joseph at

Read More »
Health-Plans-Expansion-of-Bariatric-Surgery-Transcarent-launches-Comprehensive-Multimodal-Obesity-Care-the-GLP-1-Gold-Rush

Health Plans Expansion of Bariatric Surgery; Transcarent launches Comprehensive Multimodal Obesity Care; the GLP-1 Gold Rush

AT A GLANCE Modern Healthcare reports ‘…Health insurance companies are expanding their coverage of bariatric surgery amid rising demand for pricey new weight loss drugs.’ Transcarent launches the ‘…First comprehensive Weight Health care experience…’ this week. ‘Drive through GLP-1 providers and the gold rush of companies offering telehealth weight-loss services, in Modern Healthcare. The Ozempic Plateau by Sarah Zhang at The Atlantic NEWS Nona Tepper

Read More »
Scroll to Top
Skip to content